Prognosis and risk

Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis‐Related Acquired Factor X Deficiency

Cetin O, Staron A, Teodorescu P, Sloan JM, Sanchorawala V, Szalat R

American Journal of Hematology100(12):2416-2420DOI: Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis‐Related Acquired Factor X DeficiencyPubMed: Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis‐Related Acquired Factor X Deficiency

Deciphering racial disparities in multiple myeloma outcomes

Bertrand KA, Szalat R

Blood Advances8(1):234-235DOI: Deciphering racial disparities in multiple myeloma outcomesPubMed: Deciphering racial disparities in multiple myeloma outcomes

Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes

Gustine JN, Szalat RE, Staron A, Joshi T, Mendelson L, Sloan JM, Sanchorawala V

Haematologica108(6):1680-1684DOI: Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomesPubMed: Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes

Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study

Gustine JN, Staron A, Szalat RE, …, Sanchorawala V

American Journal of Hematology97(9):1189-1199DOI: Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal studyPubMed: Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study

Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis

Acevedo J, Doros G, Szalat R, Sanchorawala V

Clinical Lymphoma Myeloma and Leukemia21(6):425-426DOI: Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL AmyloidosisPubMed: Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis

Genetic Predictors of Mortality in Patients with Multiple Myeloma

Hassan H, Szalat R

The Application of Clinical GeneticsVolume 14:241-254DOI: Genetic Predictors of Mortality in Patients with Multiple MyelomaPubMed: Genetic Predictors of Mortality in Patients with Multiple Myeloma

Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study

Fillmore NR, Cirstea D, Munjuluri A, …, Szalat RE, Munshi NC

Blood Advances5(18):3511-3514DOI: Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA studyPubMed: Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study

Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma

Ruiz-Heredia Y, Ortiz-Ruiz A, Samur MK, …, Szalat R, …, Gallardo M

Cancers13(13):3189DOI: Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple MyelomaPubMed: Pathogenetic and Prognostic Implications of Increased Mitochondrial Content in Multiple Myeloma

Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab

Szalat RE, Gustine J, Sloan JM, Edwards CV, Sanchorawala V

American Journal of Hematology97(1):79-89DOI: Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumabPubMed: Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Samur MK, Aktas Samur A, Fulciniti M, Szalat R, …, Munshi NC

Journal of Clinical Oncology38(27):3107-3118DOI: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome GroupPubMed: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group

Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis

Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V

Leukemia35(3):916-919DOI: Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosisPubMed: Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis

Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study

Fillmore NR, La J, Szalat RE, …, Munshi NC

JNCI: Journal of the National Cancer Institute113(6):691-698DOI: Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs StudyPubMed: Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Walker BA, Mavrommatis K, Wardell CP, …, Szalat R, …, Morgan G

Leukemia33(1):159-170DOI: A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysisPubMed: A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

Samur MK, Minvielle S, Gulla A, …, Szalat R, …, Munshi NC

Leukemia32(12):2626-2635DOI: Long intergenic non-coding RNAs have an independent impact on survival in multiple myelomaPubMed: Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

Maura F, Petljak M, Lionetti M, …, Szalat R, …, Bolli N

Leukemia32(4):1043-1047DOI: Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell linesPubMed: Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Fulciniti M, Martinez-Lopez J, Senapedis W, …, Szalat R, …, Munshi NC

Blood129(16):2233-2245DOI: Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myelomaPubMed: Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma

Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

Cohen C, Royer B, Javaugue V, Szalat R, …, Bridoux F

Kidney International88(5):1135-1143DOI: Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition diseasePubMed: Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Leleu X, Fouquet G, Hebraud B, …, Szalat R, …, (IFM) OBOIFDM

Leukemia27(11):2242-2244DOI: Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaPubMed: Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma

Non-random patterns of multiple primary malignancies in the era of cancer survival.

George T, Nannini K, Bihn JR, Samur MK, Szalat RE, DuMontier C, Fillmore N, Munshi NC

Journal of Clinical Oncology44(16_suppl):10584-10584DOI: Non-random patterns of multiple primary malignancies in the era of cancer survival.

Real-world one-year comparative outcomes of quadruplet and triplet induction regimens in older, transplant-ineligible multiple myeloma patients.

Cetin O, Teker G, Szalat RE

Journal of Clinical Oncology44(16_suppl):7567-7567DOI: Real-world one-year comparative outcomes of quadruplet and triplet induction regimens in older, transplant-ineligible multiple myeloma patients.

Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency

Cetin O, Teodorescu P, Staron A, Sanchorawala V, Szalat RE

Blood144(Supplement 1):4671-4671DOI: Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency

Epidemiological Characteristics and Clinical Outcomes of Patients with Monoclonal Gammopathy of Renal Significance (MGRS) Diagnosed in a Large Safety-Net Hospital in the US

Granina E, Henderson J, Bertrand KA, Sanchorawala V, Szalat RE

Blood144(Supplement 1):4680-4680DOI: Epidemiological Characteristics and Clinical Outcomes of Patients with Monoclonal Gammopathy of Renal Significance (MGRS) Diagnosed in a Large Safety-Net Hospital in the US

OAB-021: High-risk multiple myeloma due to extramedullary disease-like gene expression induced by bone marrow stromal cells

Binder M, Szalat R, Fulciniti M, Avet-Loiseau H, Parmigiani G, Samur M, Munshi N

Clinical Lymphoma Myeloma and Leukemia22:S13DOI: OAB-021: High-risk multiple myeloma due to extramedullary disease-like gene expression induced by bone marrow stromal cells

Chromatin Remodeling and Associated Changes in Gene Expression Induced By Bone Marrow Stromal Cells Identify Features of High-Risk Multiple Myeloma

Binder M, Szalat RE, Fulciniti M, Parmigiani G, Samur MK, Munshi NC

Blood138(Supplement 1):2672-2672DOI: Chromatin Remodeling and Associated Changes in Gene Expression Induced By Bone Marrow Stromal Cells Identify Features of High-Risk Multiple Myeloma

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Muchtar E, Dispenzieri A, Wisniowski B, …, Szalat R, …, Gertz MA

Blood138(Supplement 1):2720-2720DOI: Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab

Szalat R, Gustine J, Sloan JM, Sanchorawala V

Blood138(Supplement 1):2734-2734DOI: Predictive Factors of Overall Survival in Patients with Relapsed AL Amyloidosis Treated with Single Agent Daratumumab

Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

Shah P, Aktas-Samur A, Fulciniti M, Szalat R, …, Samur MK

Blood138(Supplement 1):461-461DOI: Presence of Extrachromosomal DNA (ecDNA) Impacts Both Progression Free and Overall Survival and Is an Independent Poor Prognostic Marker in Multiple Myeloma

Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Acevedo J, Doros G, Szalat R, Sloan JM, Sarosiek S, Sanchorawala V

Blood134(Supplement_1):5447-5447DOI: Clinical Characteristics, Treatment Regimens and Survival in Elderly Patients with AL Amyloidosis in a Tertiary Referral Center

Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

Prabhala R, Samur MK, Talluri S, …, Szalat R, …, Munshi NC

Blood134(Supplement_1):1784-1784DOI: Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study

Recurrent somatic Alterations in the Non-Coding Genome Alter Gene Expression Levels and Correlate With Clinical Outcome

Samur M, Samur A, Szalat R, …, Munshi N

Clinical Lymphoma Myeloma and Leukemia19(10):e12-e13DOI: Recurrent somatic Alterations in the Non-Coding Genome Alter Gene Expression Levels and Correlate With Clinical Outcome

A NOVEL PREDICTIVE MODEL COMBINING LINCRNAS AND PROTEIN CODING GENES IN MULTIPLE MYELOMA

Samur M, Gulla A, Fulciniti M, Szalat R, Samur AA, Shamas M, et al.

HAEMATOLOGICA102:495-496

Abnormalities in mitochondrial DNA copy number have pathogenetic and prognostic implications in multiple myeloma

Ruiz-Heredia Y, Samur MK, Ortiz-Ruiz A, Fernández RA, et al.

Blood, The Journal of the American Society of Hematology130(Suppl_1):4378 …

Abstract 5719: Long intergenic non-coding RNAs: a new independent risk predictors in multiple myeloma

Samur MK, Gulla A, Fulciniti M, …, Szalat R, …, Munshi N

Cancer Research77(13_Supplement):5719-5719DOI: Abstract 5719: Long intergenic non-coding RNAs: a new independent risk predictors in multiple myeloma

PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldestrostom Macroglobulinemia

Li N, Fulciniti M, Lopez MA, …, Szalat R, …, Munshi N

Blood130(Suppl_1):648-648DOI: PAK4 Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldestrostom Macroglobulinemia

Perturbation in B Cell-Subsets Can Explain the Observed Suppression of Uninvolved Immunoglobulins and Their Impact on T Tell-Subsets As Well As Patients Outcome in Myeloma

Prabhala R, Acharya S, Stekla M, Talluri S, Szalat R, Nanjappa P, et al.

Blood130:3049

Ywhae Located on Chromosome 17p13 Promotes Myeloma Cells Proliferation Via Induction of Anti-Apoptosis and Survival Signaling Pathways

Xu Y, Fulciniti M, Samur MK, Szalat R, Ho M, Lopez MA, Li N, Lin J, et al.

Blood, The Journal of the American Society of Hematology130(Suppl_1):1755 …

A targeted sequencing approach in multiple myeloma reveals a complex landscape of genomic lesions that has implications for prognosis

Bolli N, Biancon G, Gimondi S, Li Y, Sathiaseelan V, Maura F, Carniti C, et al.

HAEMATOLOGICA101(Suppl. 1):160-160

Nucleotide Excision Repair (NER) Is Frequently Impaired and Affects Outcome in Multiple Myeloma (MM)

Szalat R, Dreze M, Samur MK, …, Munshi NC

Blood124(21):2055-2055DOI: Nucleotide Excision Repair (NER) Is Frequently Impaired and Affects Outcome in Multiple Myeloma (MM)

IgM Hevylite Assay as a Biomarker of Clinical Outcome in Patients with Anti-MAG Neuropathy: P-457

ARNULF B, BENGOUFA D, LAZARETH A, SZALAT R, MALPHETTES M, et al.

Clinical Lymphoma, Myeloma & Leukemia13:s254-s255

Prognostic Value of the Different MMSET Gene Breakpoints and Correlation with Immunoglobulin Isotype and FGFR3 Expression in 173 Patients with t(4;14) Multiple Myeloma

Arnulf B, Lazareth A, Soulier J, …, Szalat R, …, Fermand JP

Blood120(21):3971-3971DOI: Prognostic Value of the Different MMSET Gene Breakpoints and Correlation with Immunoglobulin Isotype and FGFR3 Expression in 173 Patients with t(4;14) Multiple Myeloma

Total Body Irradiation (TBI) or Busulfan (Bu) Plus High Dose Melphalan After Bortezomib (Bz) Containing Regimen As Front Line Treatment of High Risk Multiple Myeloma (MM) Patients with 17p Deletion and/or t(4;14) Translocation

Arnulf B, Szalat R, Karlin L, Harel S, Asli B, Malphettes M, Soulier J, Fermand JP

Blood118(21):4501-4501DOI: Total Body Irradiation (TBI) or Busulfan (Bu) Plus High Dose Melphalan After Bortezomib (Bz) Containing Regimen As Front Line Treatment of High Risk Multiple Myeloma (MM) Patients with 17p Deletion and/or t(4;14) Translocation